New Approaches to T-Cell Acute Lymphoblastic Leukemia

H&O How common is T-cell acute lymphoblastic leukemia (T-ALL)? DT ALL is uncommon, accounting for approximately 6700 new diagnoses per year in the United States. Between […]

Management of Acute Lymphoblastic Leukemia in Older Adults

Abstract: Acute lymphoblastic leukemia, commonly known to affect the younger population, is a disease that is affecting the elderly in an increasing amount as the human […]

Emerging Data for Venetoclax in Chronic Lymphocytic Leukemia

H&O What study data led the US Food and Drug Administration (FDA) to approve venetoclax for chronic lymphocytic leukemia (CLL)? SO In CLL, venetoclax (Venclexta, AbbVie/Genentech) […]

Highlights in Leukemia and Lymphoma From the 63rd American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 63rd ASH Meeting and Exposition December 11-14, 2021 • Atlanta, Georgia The Combination of Umbralisib Plus Ublituximab Is Active […]

Highlights in Chronic Lymphocytic Leukemia From the 63rd American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 63rd ASH Meeting and Exposition • December 11-14, 2021 • Atlanta, Georgia Three-Year Follow-Up of the ASCEND Trial: Acalabrutinib […]

Highlights in Chronic Lymphocytic Leukemia From the 2021 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2021 ASCO Annual Meeting • June 4-8, 2021 First Results of a Head-to-Head Trial of Acalabrutinib vs […]

Highlights in Chronic Lymphocytic Leukemia From the 62nd American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the All-Virtual 62nd ASH Meeting and Exposition • December 5-8, 2020 Updated Safety and Efficacy Results From a Phase […]

Highlights in Chronic Lymphocytic Leukemia From the 2020 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2020 ASCO Meeting Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND […]

Highlights From the XVIII International Workshop on Chronic Lymphocytic Leukemia

A Review of Selected Presentations From the XVIII iwCLL • September 20-23, 2019 • Edinburgh, Scotland Ibrutinib Versus Placebo in Patients With Asymptomatic, Treatment-Naive Early-Stage Chronic […]

Highlights in Chronic Lymphocytic Leukemia From the 60th American Society of Hematology Annual Meeting

A Review of Selected Presentations From the 60th American Society of Hematology Annual Meeting • December 1-4, 2018 • San Diego, California Ibrutinib Alone or […]

Hem/Onc News

Ivosidenib Approved for Relapsed or Refractory Acute Myeloid Leukemia On July 20, the US Food and Drug Administration (FDA) approved ivosidenib (Tibsovo, Agios) for adults with […]

Clinical Implications of the 2018 iwCLL Guidelines Update

Plus Highlights in Chronic Lymphocytic Leukemia From the 23rd Congress of the European Hematology Association • June 14-17, 2018 • Stockholm, Sweden Clinical […]

Highlights in Chronic Lymphocytic Leukemia From the 2018 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2018 American Society of Clinical Oncology Annual Meeting • June 1-5, 2018 • Chicago, Illinois Phase 2 CAPTIVATE […]

Highlights in Acute Myeloid Leukemia From the 2017 American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 2017 American Society of Hematology Annual Meeting and Exposition • December 9-12, 2017 • Atlanta, Georgia Continuing Enasidenib Treatment […]

Hem/Onc News

First Gene Therapy Approved for Use in Acute Lymphoblastic Leukemia The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah, Novartis), the first chimeric antigen […]

Identifying Patients With Leukemia Who Are at Risk for Fungal Infections

H&O Approximately how many patients with leukemia will develop fungal infections? VB The risk of fungal infection varies according to several factors, such as the […]

Common Fungal Infections in Patients With Leukemia

H&O What is the mortality associated with fungal infections in patients with leukemia? EW Acute myeloid leukemia (AML) constitutes the hematologic malignancy with the highest […]

Guideline Recommendations for the Prophylaxis of Invasive Aspergillosis in AML

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Eunice S. Wang, MD Chief, Leukemia Service Professor of Oncology, Department of Medicine Roswell […]

CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Clinical Advances in Hematology & Oncology October 2016, Volume 14, Issue 10 Marco L. Davila, MD, PhD, and Renier J. Brentjens, MD, PhD Dr Davila is […]